MDXG - MiMedx Group, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.6000
+0.1090 (+3.12%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.4910
Open3.5000
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range3.5000 - 3.6500
52 Week Range2.2800 - 7.9500
Volume86,029
Avg. Volume286,228
Market Cap397.962M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-0.2840
Earnings DateApr 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-9% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      MiMedx Announces Settlement of VA Pricing Investigation

      MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Department of Justice (the “DOJ”), resolving an investigation concerning the accuracy of commercial pricing disclosures to the United States Department of Veterans Affairs (the “VA”) for one of the Company’s products in connection with the Company’s Federal Supply Schedule contract, and a related qui tam action filed in Minnesota. The Company self-disclosed the matter to the VA Office of Inspector General (VA-OIG) in November 2018, prior to its knowledge of the qui tam suit or any underlying government investigation and, as DOJ acknowledged in the settlement agreement, the Company cooperated with the government’s investigation into the matter.

    • PR Newswire

      MiMedx Names Peter M. Carlson as Chief Financial Officer

      MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Peter M. Carlson, Executive Vice President of Finance, has been named as the Company's Chief Financial Officer, effective immediately.

    • PR Newswire

      MiMedx Announces Filing of 2018 Annual Report

      MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2018 Annual Report, which includes the Company's audited consolidated statements of operations, and stockholders' equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.

    • GuruFocus.com

      Baillie Gifford Takes Aim at Stock Lending and Short Sellers

      The asset manager is unconvinced of its value to price discovery Continue reading...

    • PR Newswire

      MiMedx Announces Addition of Peter M. Carlson

      MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Peter M. Carlson as Executive Vice President, Finance, effective December 16, 2019. Mr. Carlson brings more than thirty years of comprehensive financial expertise having held positions as a Fortune 50 principal accounting officer and Big Five audit partner, as well as a senior Finance executive. He will be assisting the Company in the transition of financial duties with the departure of former Interim Chief Financial Officer, Edward J. Borkowski.

    • PR Newswire

      MiMedx Provides Update Regarding Timing of Restatement

      MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it expects to file its annual report on Form 10-K for the years ended December 31, 2018, 2017 and 2016 in early 2020.

    • Reuters

      UPDATE 1-Ex-CEO, COO of biotech firm MiMedx charged with securities fraud

      Two former executives of biotech company MiMedx Group Inc were criminally charged on Tuesday with fraudulently inflating the company's revenue. Former MiMedx Chief Executive Parker Petit and former Chief Operating Officer William Taylor were charged with securities fraud and conspiracy in an indictment in Manhattan federal court. "Pete Petit adamantly denies the charges leveled against him today, and he will vigorously defend himself in court," Petit' s lawyer, Eric Bruce, said in a statement.

    • Reuters

      Ex-CEO, COO of biotech firm MiMedx charged with securities fraud

      Two former executives of biotech company MiMedx Group Inc were criminally charged on Tuesday with fraudulently inflating the company's revenue. Former MiMedx Chief Executive Parker Petit and former Chief Operating Officer William Taylor were charged with securities fraud and conspiracy in an indictment in Manhattan federal court. "Pete Petit adamantly denies the charges leveled against him today, and he will vigorously defend himself in court," Petit' s lawyer, Eric Bruce, said in a statement.

    • PR Newswire

      MiMedx Announces Securities and Exchange Commission Settlement

      MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Securities and Exchange Commission (the "SEC"), resolving a previously disclosed investigation into the Company's financial accounting practices.

    • PR Newswire

      MiMedx Names William "Butch" Hulse as General Counsel and Secretary

      MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of William "Butch" Hulse as its new General Counsel and Secretary, effective December 2, 2019. With more than twenty years' experience in large law firms and life sciences organizations, Mr. Hulse brings to MiMedx legal, risk management, compliance and operational expertise and a track record of success.

    • Benzinga

      12 Stocks With Short Ratios Above 50

      Short interest can be an extremely helpful too for traders looking to get a feel for how a stock might react to a catalyst or gauge the overall bullish or bearish sentiment in a stock. Stocks with extremely ...

    • PR Newswire

      MiMedx Announces Resignation of Board Member

      MARIETTA, Ga., Sept. 20, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Luis A. Aguilar has notified the Company of his resignation from the Board of Directors. Dr. Kathleen Behrens Wilsey, Chair of the MiMedx Board of Directors, stated, "On behalf of the Board and the Company, we thank Luis for his commitment and contributions.

    • PR Newswire

      MiMedx Announces Agreement Regarding 2019 and 2020 Shareholder Meetings

      MARIETTA, Ga. , Aug. 8, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics ...

    • PR Newswire

      MiMedx Shareholders Overwhelmingly Support Election of All Three of MiMedx's Highly Qualified Director Nominees

      Preliminary Vote Count Indicates that MiMedx's Director Nominees Received Support from Approximately 80% of the Votes Cast MiMedx Shareholders Reject Petit Group's Proposal to Hold 2019 Meeting in August ...

    • PR Newswire

      MiMedx Urges Shareholders to Vote Today "FOR" All of the Board's Highly Qualified Nominees on the BLUE Proxy Card

      MARIETTA, Ga., June 14, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, encourages shareholders to vote "FOR" all of the Board's highly qualified nominees online or by telephone by following the easy instructions on the BLUE Proxy Card. The 2018 Annual Meeting of Shareholders (the "Annual Meeting") will be held on Monday, June 17, 2019 – shareholders are urged to vote the BLUE proxy card TODAY.

    • PR Newswire

      MiMedx Highlights Skills and Experience of Director Nominees

      Company Urges Shareholders to Vote with the BLUE Card Online or By Phone Today MARIETTA, Ga. , June 13, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), ...